B01 - RFI - EIDS Thailand.pdf

Subject: Armed Forces Research Institute of Medical Sciences (AFRIMS) Emerging Infectious Disease Surveillance Support Services in Thai Clinical Sites

Requiring Activity Name: Armed Forces Research Institute of Medical Sciences (AFRIMS)

THIS IS NOT A REQUEST FOR PROPOSALS (RFP) OR A REQUEST FOR QUOTATIONS

(RFQ); IT IS STRICTLY A REQUEST FOR INFORMATION (RFI). NEITHER UNSOLICITED

PROPOSALS NOR ANY OTHER KINDS OF OFFERS WILL BE CONSIDERED IN RESPONSE

TO THIS RFI. NO CONTRACT WILL BE AWARDED PURSUANT TO THIS

ANNOUNCEMENT.

1.0 DISCLAIMER: This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. All information received in response to this RFI that is marked Proprietary will be handled accordingly. Responses to the RFI will not be returned. At this time, questions concerning the composition and requirements for a future RFP will not be entertained.

2.0 SUBJECT: This is a summary of the Performance Work Statement for this requirement. The Contractor shall provide non-personal support service(s) in support of AFRIMS for the surveillance of emerging infectious diseases and clinical trials in health care facilities in Thailand. This will include clinical research and laboratory services. Pathogens that may be the subject of surveillance studies include Burkholderia mellioidosis, febrile-causing pathogens, sexually transmitted pathogens, respiratory pathogens, enteric pathogens, antimicrobial resistant bacteria, agents of parasitic disease including malaria, and other emerging infections. This support will include advertisement, the rental of space at the site for enrollment, subject enrollment, subject compensation, sample collection, sample processing, point-of-care and preliminary testing, sample storage, sample transport, laboratory advanced testing, consolidation and analysis of data, writing reports, and training. The Contractor shall apply the principles of Good Clinical Practice (GCP) and Good Clinical Laboratory Practices (GCLP) in all aspects of the study, meeting quality and management standards to ensure clinical trial and infectious disease surveillance projects are conducted with integrity, accuracy, and completeness. The Contractor shall coordinate with AFRIMS and the study teams in the execution of the projects, to include: organization and personnel, facilities, patient enrollment, maintaining adequate supply of materials and reagents, standard operating procedures in sample management encompassing sample collection, transport and chain of custody, sample storage/retention of samples, proper record keeping/reporting, ensuring reports are available for quality control/quality audits, and training staff involved in the study.

3.0 BACKGROUND: AFRIMS seeks to conduct research projects involving surveillance for emerging infectious diseases and conduct clinical trials within Thailand with a focus on Burkholderia mellioidosis.

4.0 RESPONSE INSTRUCTIONS: Respondents should address the following in their capabilities statement:

(A) Technical Experience: Contractor’s technical experience pertinent to effective execution of the tasks outlined in section 2; and

(B) In their capability statement, responders are to identify if such similar services, existing or occurring, are being provided commercially.

5.0 CAPABAILITY STATEMENT FORMAT: Contractor’s capability statements are limited to 15 pages. The response shall be single spaced. Each paragraph shall be separated by at least one blank line. A standard, 12-point minimum font size applies. Times New Roman font is required. Tables and illustrations may use a reduced font size no less than 8-point and may be landscape. The cover page does not count in the page count.

6.0 ESTIMATED PERIOD OF PERFORMANCE: December 2023 – November 2028

7.0 CONTACT INFORMATION: No questions will be addressed. All information regarding Capabilities Statements or any other proprietary information relative to this RFI shall be submitted via email to joshua.r.dean2.civ@health.mil no later than 11:00am EST on Friday, 20 October 2023.